In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, birth defects and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. The proposed research aims to assess time-restricted eating in the 2nd and 3rd trimesters of pregnancy to explore the effects on maternal weight, and perinatal health outcomes compared to standard clinical care.
Severe obesity is a contributor to adverse perinatal outcomes. The prevalence of severe obesity is on the rise in the United States (U.S.), having increased from 6.4% of the adult population in 2011-2012 to just over 9% of adults in 2017-2018. The prevalence of severe obesity among reproductive age females is approximately 10%. This is an alarming statistic given severe obesity is a predictor of adverse perinatal outcomes including gestational diabetes mellitus, preeclampsia, premature birth (both spontaneous and medically indicated), and at its most severe, fetal death, birth defects, and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. Existing lifestyle interventions (calorie control/dietary pattern changes/physical activity) have showed modest effects on attenuating excess gestational weight gain and modest effects on perinatal health outcomes among pregnant females with obesity. Time- restricted eating, where an individual simply watches the clock and consumes calories within a particular eating window, is a simple and highly accessible eating pattern that has the potential to minimize gestational weight gain, reduce excess glucose and lipids, and improve metabolic health among pregnant females with severe obesity all of which could translate to improved perinatal health outcomes. Yet there are no clinical trials of time-restricted eating in pregnancy. The investigators aim to test the safety, feasibility, and acceptability of time-restricted eating among 60 pregnant females with severe obesity. The investigators will examine time-restricted eating safety, feasibility and acceptability (8-hr eating window in the 2nd trimester \& 10-hr eating window in the 3rd trimester), and explore its effects on weight, cardiometabolic risk markers and perinatal health outcomes vs. Standard Care. The intervention will begin between 14 - \< = 20 weeks gestational age and continue through admission for labor and delivery. The study will involve weekly meetings with a nutritionist, and research visits at baseline (\~17 weeks gestational age), 27-29 weeks gestational age and 35-37 weeks gestational age as well as monthly check-ins for maternal and fetal health monitoring. Maternal and neonatal data from labor and delivery will also be collected from electronic health records. Glucose will be continuously monitored for 10 days at 20 weeks gestational age and 34 weeks gestational age (optional). The goal of our work is to reduce and prevent adverse perinatal outcomes among pregnant females with severe obesity. Given the relative simplicity of time-restricted eating it can be easily disseminated in clinic demonstrating its strong potential for wide-scale public health impact.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
60
The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily (10am - 6pm OR 11am - 7pm) in the 2nd trimester and 10-hr eating window from (9am - 7pm OR 10am - 8pm) in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
University of Illinois at Chicago College of Applied Health Sciences
Chicago, Illinois, United States
RECRUITINGRecruitment Feasibility
≥ 30% of those approached enroll
Time frame: From 6 months through 32 months (the funding period is 36 months)
Trial safety - Maternal Complete Blood Count
% and n with abnormal results by study arm
Time frame: Baseline (14-20 weeks gestational age) and monthly through labor and delivery, about 6 months
Trial safety - Non-stress Test for Fetal Safety
Measured with a fetal monitor to examine baby's heart rate over time (usually 20 to 30 minutes, but sometimes up to an hour) % and n with abnormal results by study arm
Time frame: 29-31 weeks gestational age and 35-37 weeks gestational age
Intervention acceptability
Semi-structured interviews
Time frame: 25-27 weeks gestational age and 35-37 weeks gestational age
Research visit feasibility
Number of data collection visits completed with \>=80% completed at each timepoint and completeness of data
Time frame: Baseline, 25-27 weeks gestational age and 35-37 weeks gestational age
Intervention (TRE) session feasibility
Number and % of intervention sessions completed by TRE participants
Time frame: Weekly from baseline through labor and delivery, about 6 months
TRE adherence
Response rate to daily text message regarding eating start and stop time to determine adherence to the eating window goal is \>= 80% adherence on days reported
Time frame: Daily from enrollment to labor and delivery (TRE arm only), about 6 months
Trial safety - Maternal health checks
Weekly maternal health checks via videoconference in TRE and control group that is verified with electronic health record
Time frame: Weekly from baseline to labor and delivery, about 6 months, % and n for health events reported by study arm
Trial safety - Maternal outcomes
Data obtained from the participant's electronic health record (gestational age at delivery, gestational diabetes, gestational hypertension, preeclampsia, c-section, spontaneous pre-term birth, iron deficiency anemia) % and n with abnormal results by study arm
Time frame: Labor and delivery
Trial safety - Neonatal outcomes
Data obtained from the participant's electronic health record (small or large for gestational age, neonatal intensive care admission, jaundice, APGAR score) % and n with abnormal results by study arm
Time frame: Labor and delivery
Trial Retention
n and % of women retained through the final in-person data collection with \>= 80% retained
Time frame: 35-37 week gestational age
Maternal Body Weight
Body weight in kilograms
Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Blood Glucose
Measured in serum
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Insulin
Measured in serum
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Fasting Blood Lipids
Cholesterol and triglycerides
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal C-reactive protein
Measured in plasma
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Systolic Blood Pressure
Measured with participant in a seated position using an automated cuff
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Diastolic Blood Pressure
Measured with participant in a seated position using an automated cuff
Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age
Maternal Hb A1c
Measured from whole blood
Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.